MEDAREX, INC. NONQUALIFIED STOCK OPTION AGREEMENT FOR 2005 EQUITY INCENTIVE PLANMedarex Inc • August 6th, 2007 • Services-commercial physical & biological research • New Jersey
MEDAREX, INC., a New Jersey corporation (the “Company”), in consideration of the value to it of the continuing services of HOWARD H. PIEN (hereinafter called “Optionee”), which continuing services the grant of this Option is designed to secure, and in consideration of the various undertakings made herein by Optionee, and pursuant to its 2005 Equity Incentive Plan (hereinafter called the “Plan”), hereby grants to Optionee an option (the “Option”), evidenced by this Option Agreement, exercisable for the period and upon the terms hereinafter set out, to purchase 500,000 shares (the “Option Amount”) of $.01 par value common stock of the Company (“Common Stock”) at a price of $14.355 per share (the “Option Price”), which price represents at least the Fair Market Value (as such term is defined in the Plan) of the shares as of the Date of Grant (as hereinafter defined).
ORPHAN DRUG EXCLUSIVITY WAIVER AGREEMENTOrphan Drug Exclusivity Waiver Agreement • August 6th, 2007 • Medarex Inc • Services-commercial physical & biological research
THIS ORPHAN DRUG EXCLUSIVITY WAIVER AGREEMENT (the “Agreement”) is entered into as of April 25, 2007 (the “Effective Date”) by and between Pfizer Inc, a Delaware corporation having an office at 235 East 42nd Street, New York, New York 10017 (“Pfizer”), Bristol-Myers Squibb Company, a Delaware corporation headquartered at 345 Park Avenue, New York, New York 10154 (“BMS”) and Medarex, Inc., a New Jersey corporation with a business address at 707 State Road, Princeton, NJ 08540 (“Medarex”). Pfizer, BMS and Medarex each may be referred to herein individually as a “Party” or collectively as the “Parties.”
RESTRICTED STOCK AGREEMENTRestricted Stock Agreement • August 6th, 2007 • Medarex Inc • Services-commercial physical & biological research • New Jersey
This Agreement (the “Agreement”) is made as of the 29th day of June, 2007 (“Date of Award”), between Medarex, Inc., a New Jersey corporation (the “Company”), and Howard H. Pien (the “Grantee”). In consideration of the agreements set forth below, the Company and the Grantee agree as follows:
AMENDMENT NO. 1 TO COLLABORATION AND CO-PROMOTION AGREEMENTCollaboration and Co-Promotion Agreement • August 6th, 2007 • Medarex Inc • Services-commercial physical & biological research
THIS AGREEMENT (“Amendment”) is made and entered into effective as of April 25, 2007 (the “Amendment Effective Date”) by and between Medarex, Inc., a New Jersey corporation having its principal place of business at 707 State Road, Princeton, New Jersey 08540-1437 (“Medarex”) and Bristol-Myers Squibb Company, a Delaware corporation headquartered at 345 Park Avenue, New York, New York 10154 (“BMS”), and amends the COLLABORATION AND CO-PROMOTION AGREEMENT (the “Agreement”) made as of November 7, 2004 between Medarex and BMS. Medarex and BMS are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDMENT TO CROSS-LICENSE AGREEMENTLicense Agreement • August 6th, 2007 • Medarex Inc • Services-commercial physical & biological research
THIS AMENDMENT TO CROSS-LICENSE AGREEMENT (the “Amendment”) is made as of April 25th, 2007 (the “Amendment Effective Date”) between Pfizer Inc, a Delaware corporation having an office at 235 East 42nd Street, New York, New York 10017, and its Affiliates (“Pfizer”), and Medarex, Inc., a New Jersey corporation with a business address at 707 State Road, Princeton, New Jersey 08540 (“Medarex”). Pfizer and Medarex each may be referred to herein individually as a “Party” or collectively as the “Parties.”
